Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Hetero is hiring 1 role related to this product
Company
Hetero
India - Hyderabad
RITONAVIR (ritonavir) by Hetero is hiv protease inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection ( ). First approved in 2018.
Drug data last refreshed 9h ago
HIV Protease Inhibitors
Cytochrome P450 3A Inhibitor
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
Worked on RITONAVIR at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moHetero is hiring 1 role related to this product